- | MeiraGTx
MeiraGTx Reveals Interim Data From Phase 1 Trial Of Radiation-Induced Dry Mouth Symptom
- | Windtree Therapeutics
Windtree Therapeutics CEO Craig Fraser – Breaking Down Acute Heart Failure (Video)
Windtree Therapeutics CEO Craig Fraser is a military vet with 30 years experience in biotech, including at Pfizer and J&J.
- | Cerevance
Cell-Type-Specific Analyses
Guide Efforts against Brain Disease
Cerevance is working to change that. Proprietary
technology that accurately determines brain age and
relates it to Alzheimer’s, Parkinson’s, and other brain
diseases is providing novel insights that inform therapeutic development
- | DURECT
Epigenetic Therapies Start Operating Outside the Lines
Durect focuses on eliminating the epigenetic faults that cause cells to become dysfunctional. Following this approach, Durect intends to generate drugs that can treat acute organ injury and chronic liver diseases.
- | SOTIO
Little European biotech Sotio nabs a super $316M funding round for its superagonist work
Sotio is also working on earlier efforts, including BOXR1030, its next-gen CAR-T program for solid tumors expressing GPC3 and based on its so-called BOXR platform “that aims to enhance the fitness of T cells in the hostile tumor microenvironment,” according to the Prague-based company.
- | Sio Gene Therapies
Rare disease with fatal diagnosis doesn’t stop this woman from living life – and helping others
Last month, Jessie Jackson’s friends and family sang her happy birthday a little early. Jessie doesn’t turn 30 until Dec. 12, but for the past five years on the anniversary of her diagnosis, her parents have hosted a fundraiser. They weren’t taking any chances.
- | BeyondSpring Pharmaceuticals
BeyondSpring CEO Dr. Lan Huang – Targeting Cancer (Video)
BeyondSpring is a clinical stage biopharma focused on immuno-oncology cancer therapies. It developed Plinabulin for chemotherapy-induced neutropenia and non-small cell lung cancer. CEO and co-founder Dr. Lan Huang, a structural biologist by training, joined us to discuss Q4 milestones, the potential for Plinabulin, industry trends, 2022 outlook and why small molecule therapy is never going to go away.
- | Cardiff Oncology
Pfizer doles out $15M to Cardiff to advance a challenger to Amgen’s KRAS winner Lumakras
Pfizer must have liked what it saw in data presented by Cardiff Oncology for a challenger in KRAS-mutated cancers. The Big Pharma is putting up a $15 million equity investment in the biotech to help bankroll development of the drug.
